Organ-specific pancreatic tumor growth properties and tumor immunity

Keita Morikane, Richard M. Tempero, Connie L. Sivinski, Mitsuharu Nomoto, Michelle L. Van Lith, Tetsuichiro Muto, Michael A. Hollingsworth

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


We established a model of orthotopic injection of a syngeneic pancreatic tumor cell line in C57BL/6 mice and evaluated the effects of organ site on induction of immunity to a tumor-specific antigen, MUC1. Mice were challenged with a syngeneic pancreatic adenocarcinoma cell line that expressed MUC1 (Panc02-MUC1) by orthotopic injection into the pancreas, or by subcutaneous injection. Tumor cells injected into the pancreas grew much faster than those injected subcutaneously. Mice challenged subcutaneously with Panc02-MUC1 rejected tumors or developed slowly growing tumors that were negative for MUC1 expression. In contrast, mice challenged orthotopically into the pancreas developed progressive tumors that were positive for MUC1 expression. Sera from mice that rejected Panc02-MUC1 (tumor-immune mice) showed no detectable IgG1 and IgM titers against the MUC1 tandem-repeat peptide, whereas mice with progressive tumor growth had significant titers of IgG1 and IgM specific for MUC1. This suggests that the humoral immune response was ineffective in mediating tumor rejection. The results show that the growth properties and immunological rejection of pancreatic tumors is affected by the organ site at which the tumor grows.

Original languageEnglish (US)
Pages (from-to)287-296
Number of pages10
JournalCancer Immunology Immunotherapy
Issue number5
StatePublished - 1999


  • Orthotopic injection MUC1
  • Pancreatic tumor
  • Syngeneic
  • Tumor immunity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Organ-specific pancreatic tumor growth properties and tumor immunity'. Together they form a unique fingerprint.

Cite this